These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 15908688)

  • 1. Resisting a fundamentalist policy.
    Castro M
    J Clin Oncol; 2005 May; 23(15):3645-6; author reply 3646-8. PubMed ID: 15908688
    [No Abstract]   [Full Text] [Related]  

  • 2. Chemotherapy sensitivity and response assays: are the ASCO guidelines for clinical trial design too restrictive?
    Wieand HS
    J Clin Oncol; 2005 May; 23(15):3643-4; author reply 3646-8. PubMed ID: 15908687
    [No Abstract]   [Full Text] [Related]  

  • 3. In vitro drug resistance versus chemosensitivity: two sides of different coins.
    Fruehauf JP; Alberts DS
    J Clin Oncol; 2005 May; 23(15):3641-3; author reply 3646-8. PubMed ID: 15908686
    [No Abstract]   [Full Text] [Related]  

  • 4. Developing new agents for the treatment of childhood cancer.
    Kurmasheva R; Morton C; Houghton PJ
    Curr Opin Investig Drugs; 2005 Dec; 6(12):1215-27. PubMed ID: 16372407
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Practical guidelines for diagnostic use of in vitro chemosensitivity tests.
    Schinköthe T; Haeger S; Gabri MR
    Anticancer Res; 2007; 27(3A):1365-7. PubMed ID: 17593632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Cancer chemotherapy; past, present and future--from the aspect of fundamental studies].
    Tukagoshi S
    Gan To Kagaku Ryoho; 2003 Oct; 30(10):1398-403. PubMed ID: 14584271
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical correlations for cell culture assays based on the concept of total tumor cell kill.
    Weisenthal LM
    Contrib Gynecol Obstet; 1994; 19():82-90. PubMed ID: 7995056
    [No Abstract]   [Full Text] [Related]  

  • 8. Are targeted therapies really targeted?
    Schilsky RL
    Clin Adv Hematol Oncol; 2003 Dec; 1(12):722-3. PubMed ID: 16258475
    [No Abstract]   [Full Text] [Related]  

  • 9. The role of the National Cancer Institute in drug development.
    Doroshow J
    Clin Adv Hematol Oncol; 2005 Apr; 3(4):257-8. PubMed ID: 16166997
    [No Abstract]   [Full Text] [Related]  

  • 10. Chemotherapy sensitivity and resistance assays.
    Tecnologica MAP Suppl; 2000 Jun; ():3-6. PubMed ID: 11067680
    [No Abstract]   [Full Text] [Related]  

  • 11. What's wrong with our cancer models?
    Kamb A
    Nat Rev Drug Discov; 2005 Feb; 4(2):161-5. PubMed ID: 15688078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of drug resistance in cancer chemotherapy: the Kern and DiSC assays.
    Weisenthal LM; Kern DH
    Oncology (Williston Park); 1991 Sep; 5(9):93-103; disc. 104, 111-4, 117-8. PubMed ID: 1835882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Should the FDA be the doctor of last resort?
    DeVita VT
    Nat Clin Pract Oncol; 2005 Sep; 2(9):423. PubMed ID: 16264991
    [No Abstract]   [Full Text] [Related]  

  • 14. [New therapeutic strategies in oncology].
    Bohuon C
    Ann Pharm Fr; 2010 Jul; 68(4):203-4. PubMed ID: 20637352
    [No Abstract]   [Full Text] [Related]  

  • 15. New initiatives aim to test more cancer drugs for children.
    Brower V
    J Natl Cancer Inst; 2004 Dec; 96(24):1808-10. PubMed ID: 15601634
    [No Abstract]   [Full Text] [Related]  

  • 16. Testing cancer drugs in children.
    Oncology (Williston Park); 2001 Oct; 15(10):1237-8. PubMed ID: 11702955
    [No Abstract]   [Full Text] [Related]  

  • 17. Chemosensitivity assays: still eyeing the clinic.
    Jenks S
    J Natl Cancer Inst; 2012 Dec; 104(23):1775-7. PubMed ID: 23213182
    [No Abstract]   [Full Text] [Related]  

  • 18. Resistance in malignant tumors: can resistance assays optimize cytostatic chemotherapy?
    Lippert TH; Ruoff HJ; Volm M
    Pharmacology; 2008; 81(3):196-203. PubMed ID: 18176090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug resistance in hematologic malignancies.
    Dalton W
    Clin Adv Hematol Oncol; 2005 Apr; 3(4):267-8. PubMed ID: 16166998
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical development of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors: what lessons have we learned?
    Hidalgo M
    Adv Exp Med Biol; 2008; 610():128-43. PubMed ID: 18593020
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.